FDA Approves First Direct-to-Consumer Genetic Risk Tests

The FDA has approved the first-ever genetic tests that allow consumers to determine if they are at risk for developing certain diseases or conditions.

The 23andMe Personal Genome Service Genetic Health Risk (GHR) tests check for 10 diseases or conditions based on a person’s inherited genetics. The hope is that if someone knows they may be at risk for a certain disease, their doctor will also know and take necessary steps or make lifestyle changes.

The tests work by analyzing DNA in a saliva sample, which is then examined for more than 500,000 genetic variants. The presence or absence of some of these variants is linked to an increased risk for developing certain diseases or conditions, including Parkinson’s disease, Alzheimer’s disease, celiac disease and primary dystonia, a disorder characterized by uncontrolled muscular contractions or other movements.

Risks with the tests are primarily getting false positive or false negative readings. The FDA cautions that test results should not be used to diagnose or inform a treatment decision, and should be discussed with a health care professional.


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

Can Convalescent Plasma Treat COVID-19 Patients?

Can Convalescent Plasma Treat COVID-19 Patients?

One of the most promising treatments for COVID-19 is convalescent plasma, a component of blood. People who have been infected with the virus and are now healthy have developed COVID-19-fighting antibodies, which, the theory is, can be given to people currently sick with COVID-19 so that those antibodies can boost…

  • Advertisement